MNKD 2017 Annual Report

MANNKIND CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (Continued) Year Ended December 31, 2017 2016 2015 (In thousands) CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from direct placement of common stock . . . . . . . . . . . . . . . . . . . . $61,000 $ 50,000 $ — Issuance cost associated with direct placement . . . . . . . . . . . . . . . . . . . . . . (3,310) (2,690) — Principal payments on facility financing obligation . . . . . . . . . . . . . . . . . . . (4,000) (5,000) — Payment of employment taxes related to vested restricted stock units . . . . (127) (165) (1,858) Proceeds from issuance of common stock . . . . . . . . . . . . . . . . . . . . . . . . . . — 893 4,146 Proceeds from issuance of common stock under Tel Aviv Stock Exchange . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . — — 36,142 Issuance cost associated with the Tel Aviv Stock Exchange . . . . . . . . . . . . — — (1,432) Exercise of warrants for common stock . . . . . . . . . . . . . . . . . . . . . . . . . . . . — — 10,123 Payment of senior convertible notes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . — — (64,287) Payment of debt issuance costs on senior convertible notes . . . . . . . . . . . . — — (831) Borrowings on note payable to principal stockholder . . . . . . . . . . . . . . . . . 19,429 — — Milestone payment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . — — (4,219) Proceeds from issuance of common stock pursuant to at-the-market issuance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 564 — 28,392 Issuance costs of at-the-market transactions . . . . . . . . . . . . . . . . . . . . . . . . . (17) — (548) Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24 — 40 Net cash provided by financing activities . . . . . . . . . . . . . . . 73,563 43,038 5,668 NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25,460 (36,179) (61,767) CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF PERIOD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22,895 59,074 120,841 CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $48,355 $ 22,895 $ 59,074 SUPPLEMENTAL CASH FLOWS DISCLOSURES: Income taxes paid in cash . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 51 $ — $ — Interest paid in cash, net of amounts capitalized . . . . . . . . . . . . . . . . . . . . . $ 7,728 $ 8,991 $ 13,355 NON-CASH INVESTING AND FINANCING ACTIVITIES: Payment of note obligations and interest through issuance of common stock . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $20,593 $ — $ 8,253 Non-cash construction in progress and property and equipment . . . . . . . . . $ — $ 588 $ — Reclassification of deferred payments from collaboration to Sanofi Loan Facility and loss share obligation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ — $ 5,174 $ 59,337 Reclassification of property and equipment to asset held for sale . . . . . . . . $ — $ 17,294 $ — Capitalization of interest on note payable to principal stockholder . . . . . . . $10,716 $ — $ — Reclassification of warrant liability to additional paid-in capital . . . . . . . . . $ 1,880 $ — $ — See notes to consolidated financial statements. 84